GE Healthcare to open biotechnology manufacturing centre in UK
GE Healthcare has revealed that it will open a new biotechnology manufacturing centre at the Stevenage Bioscience Catalyst (SBC) Open Innovation Campus, in Stevenage in the UK. In the first half of 2019, the centre will start producing a fibre-based purification platform, which has the potential to significantly improve efficiency in the purification steps of manufacturing biopharmaceuticals, gene therapies and viral vectors.
The fibre-based purification platform comprises material with a unique proprietary structure. This has the potential to significantly improve process speed, flexibility and robustness during purification, a key step in the manufacturing of biopharmaceuticals. Additional products will also be produced at the centre to serve both laboratory and clinical applications.
Opening this new facility, which incorporates 3000 sq. ft (280 m2) of cleanroom space will increase employee numbers at GE Healthcare’s Stevenage facility. The fibre-based purification products will be prepared in Stevenage before being further processed and finished in GE Healthcare’s existing manufacturing facility in Cardiff, Wales.
See also
- Securing, controlling and monetising genomic data with blockchain technology
- Japan’s high-quality health data and innovations present opportunities between Japan and the UK
- The Amazon-Berkshire-JPM team makes a new appointment
“This technology will bring real efficiency and productivity advantages for biopharmaceutical manufacturers as they move towards integrated, connected or continuous operations,” says Olivier Loeillot, General Manager, BioProcess at GE Healthcare Life Sciences. “The fibre-based chromatography technology developed and manufactured in Stevenage will extend GE Healthcare’s start-to-finish bioprocess purification portfolio.”
Biopharmaceuticals, such as monoclonal antibodies are the world’s fastest-growing class of medicine. The global market for biopharmaceuticals is estimated at more than $200bn, and the market is growing around eight percent annually. All the top 10 biologic drugs by global revenue use GE Healthcare technologies in their manufacture.
The purification technology to be produced at the new facility came to GE Healthcare as part of the acquisition of Puridify, in November 2017. Puridify was founded in 2013 as a spin-out from University College London (UCL) and was based at the bio-incubator facility at the SBC, where GE Healthcare maintains an open laboratory aimed at providing SBC tenants with affordable access to advanced protein and cell analysis technologies.
